Cytokinetics, Incorporated
CYTKNext catalyst
Aficamten (CK-3773274)
Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM)
Get an email about CYTK's next catalysts
Track Cytokinetics (CYTK) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (regulatory event, Phase 3 readout).See the timeline
3 upcoming, 1 past
FDA PDUFA Date Aficamten (MYQORZO)
For Obstructive hypertrophic cardiomyopathy (label update based on MAPLE-HCM). sNDA; adds to an existing approval. Verified against the company announcement on 2026-10-16.
SourceRegulatory — Myqorzo
For heart muscle disease. Cytokinetics presented detailed positive data for Myqorzo at ESC26, supporting expanded approval for a heart muscle disease indication that could potentially double the drug's market reach in 2027.
SourceOmecamtiv Mecarbil (OM) Phase 3 Est. Readout (COMET-HF)
Primary completion for Omecamtiv Mecarbil (OM) trial (NCT06736574) in Heart Failure
SourceUpcoming FDA decisions
How CYTK's past catalysts played out
Market Overview
Stock performance and key metrics
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.
Websitetirasemtiv
Amyotrophic Lateral Sclerosis (ALS)
Aficamten (CK-3773274)
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Omecamtiv Mecarbil
Heart Failure With Reduced Ejection Fraction
Omecamtiv Mecarbil (OM)
Heart Failure
Aficamten
Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
CK-1827452
Heart Failure
Reldesemtiv
Amyotrophic Lateral Sclerosis
SB-743921
Non-Hodgkin's Lymphoma
CK-3773274
Hypertrophic Cardiomyopathy (HCM)
Riluzole (Part B)
Amyotrophic Lateral Sclerosis
Omecamtiv Mecarbil Matrix F2 Formulation
Modified Release Oral Formulation
CK-2017357 (Part B)
Amyotrophic Lateral Sclerosis
CK-2017357 (Part A)
Amyotrophic Lateral Sclerosis
Omecamtiv Mecarbil Swellable Core Technology F2
Modified Release Oral Formulation
CK-2017357
Amyotrophic Lateral Sclerosis
Omecamtiv Mecarbil Matrix F1 Formulation
Modified Release Oral Formulation
Riluzole
Amyotrophic Lateral Sclerosis
CK-4021586
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
tirasemtiv | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Aficamten (CK-3773274) | Phase 3 | Obstructive Hypertrophic Cardiomyopathy (oHCM) | - | - |
Omecamtiv Mecarbil | Phase 3 | Heart Failure With Reduced Ejection Fraction | - | - |
Omecamtiv Mecarbil (OM) | Phase 3 | Heart Failure | - | - |
Aficamten | Phase 3 | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | - | - |
CK-1827452 | Phase 2 | Heart Failure | - | - |
Reldesemtiv | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
SB-743921 | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
CK-3773274 | Phase 2 | Hypertrophic Cardiomyopathy (HCM) | - | - |
Riluzole (Part B) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Omecamtiv Mecarbil Matrix F2 Formulation | Phase 2 | Modified Release Oral Formulation | - | - |
CK-2017357 (Part B) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
CK-2017357 (Part A) | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Omecamtiv Mecarbil Swellable Core Technology F2 | Phase 2 | Modified Release Oral Formulation | - | - |
CK-2017357 | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
Omecamtiv Mecarbil Matrix F1 Formulation | Phase 2 | Modified Release Oral Formulation | - | - |
Riluzole | Phase 2 | Amyotrophic Lateral Sclerosis | - | - |
CK-4021586 | Phase 2 | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | - | - |
Hypertrophic Cardiomyopathy (HCM)
1 drug in this indication
heart muscle disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Cytokinetics, Incorporated's drug pipeline?→
CatalystAlert tracks 18 drug candidates in Cytokinetics, Incorporated's (CYTK) pipeline across Phase 3, Phase 2. Its lead program is Aficamten (CK-3773274) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cytokinetics, Incorporated's next FDA catalyst?→
Cytokinetics, Incorporated's (CYTK) next tracked catalyst is a PDUFA date expected Nov 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CYTK biotech catalysts?→
Add CYTK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cytokinetics, Incorporated's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.